Modulation of Insulin Degrading Enzyme Activity and Liver Cell Proliferation

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2015 May 7

PMID 25945652

Citations 21

Authors

Olga Pivovarova

Christian von Loeffelholz

Iryna Ilkavets

Carsten Sticht

Sergei Zhuk

Veronica Murahovschi

Sonja Lukowski

Stephanie Docke

Jennifer Kriebel

Tonia de Las Heras Gala

Anna Malashicheva

Anna Kostareva

Johan F Lock

Martin Stockmann

Harald Grallert

Norbert Gretz

Steven Dooley

Andreas F H Pfeiffer

Natalia Rudovich

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus type 2 (T2DM), insulin therapy, and hyperinsulinemia are independent risk factors of liver cancer. Recently, the use of a novel inhibitor of insulin degrading enzyme (IDE) was proposed as a new therapeutic strategy in T2DM. However, IDE inhibition might stimulate liver cell proliferation via increased intracellular insulin concentration. The aim of this study was to characterize effects of inhibition of IDE activity in HepG2 hepatoma cells and to analyze liver specific expression of IDE in subjects with T2DM. HepG2 cells were treated with 10 nM insulin for 24 h with or without inhibition of IDE activity using IDE RNAi, and cell transcriptome and proliferation rate were analyzed. Human liver samples (n = 22) were used for the gene expression profiling by microarrays. In HepG2 cells, IDE knockdown changed expression of genes involved in cell cycle and apoptosis pathways. Proliferation rate was lower in IDE knockdown cells than in controls. Microarray analysis revealed the decrease of hepatic IDE expression in subjects with T2DM accompanied by the downregulation of the p53-dependent genes FAS and CCNG2, but not by the upregulation of proliferation markers MKI67, MCM2 and PCNA. Similar results were found in the liver microarray dataset from GEO Profiles database. In conclusion, IDE expression is decreased in liver of subjects with T2DM which is accompanied by the dysregulation of p53 pathway. Prolonged use of IDE inhibitors for T2DM treatment should be carefully tested in animal studies regarding its potential effect on hepatic tumorigenesis.

Citing Articles

Genome-wide association study (GWAS) identified PCOS susceptibility variants and replicates reported risk variants.

Sharma P, Senapati S, Goyal L, Kaur B, Kamra P, Khetarpal P Arch Gynecol Obstet. 2024; 309(5):2009-2019.

PMID: 38421422 DOI: 10.1007/s00404-024-07400-w.

Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging.

Corraliza-Gomez M, Bermejo T, Lilue J, Rodriguez-Iglesias N, Valero J, Cozar-Castellano I J Neuroinflammation. 2023; 20(1):233.

PMID: 37817156 PMC: 10566021. DOI: 10.1186/s12974-023-02914-7.

Neocornuside A-D, Four Novel Iridoid Glycosides from Fruits of and Their Antidiabetic Activity.

Yang M, Hao Z, Wang X, Zhou S, Zhu D, Yang Y Molecules. 2022; 27(15).

PMID: 35897906 PMC: 9331380. DOI: 10.3390/molecules27154732.

Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?.

Lesire L, Leroux F, Deprez-Poulain R, Deprez B Cells. 2022; 11(7).

PMID: 35406791 PMC: 8998118. DOI: 10.3390/cells11071228.

Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model.

Fursht O, Liran M, Nash Y, Medala V, Ini D, Royal T Front Immunol. 2022; 13:835774.

PMID: 35350789 PMC: 8958001. DOI: 10.3389/fimmu.2022.835774.

References

Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S . A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010; 12(5):483-95. DOI: 10.1016/j.cmet.2010.09.015. View

Fawcett J, Sang H, Permana P, Levy J, Duckworth W . Insulin metabolism in human adipocytes from subcutaneous and visceral depots. Biochem Biophys Res Commun. 2010; 402(4):762-6. DOI: 10.1016/j.bbrc.2010.10.104. View

Leissring M, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay S . Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One. 2010; 5(5):e10504. PMC: 2866327. DOI: 10.1371/journal.pone.0010504. View

Rudovich N, Pivovarova O, Fisher E, Fischer-Rosinsky A, Spranger J, Mohlig M . Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes. J Mol Med (Berl). 2009; 87(11):1145-51. DOI: 10.1007/s00109-009-0540-6. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33 Suppl 1:S62-9. PMC: 2797383. DOI: 10.2337/dc10-S062. View

Pihlajamaki J, Boes T, Kim E, Dearie F, Kim B, Schroeder J . Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab. 2009; 94(9):3521-9. PMC: 2741713. DOI: 10.1210/jc.2009-0212. View

Pivovarova O, Gogebakan O, Pfeiffer A, Rudovich N . Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells. Diabetologia. 2009; 52(8):1656-64. DOI: 10.1007/s00125-009-1350-7. View

Vuppalanchi R, Chalasani N . Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2008; 49(1):306-17. PMC: 2766096. DOI: 10.1002/hep.22603. View

Epting C, King F, Pedersen A, Zaman J, Ritner C, Bernstein H . Stem cell antigen-1 localizes to lipid microdomains and associates with insulin degrading enzyme in skeletal myoblasts. J Cell Physiol. 2008; 217(1):250-60. PMC: 2636697. DOI: 10.1002/jcp.21500. View

10.

Fawcett J, Permana P, Levy J, Duckworth W . Regulation of protein degradation by insulin-degrading enzyme: analysis by small interfering RNA-mediated gene silencing. Arch Biochem Biophys. 2007; 468(1):128-33. DOI: 10.1016/j.abb.2007.09.019. View

11.

Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, Boyer N . Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci. 2006; 26(23):6377-85. PMC: 6675197. DOI: 10.1523/JNEUROSCI.0651-06.2006. View

12.

Pivovarova O, Jurchott K, Rudovich N, Hornemann S, Ye L, Mockel S . Changes of Dietary Fat and Carbohydrate Content Alter Central and Peripheral Clock in Humans. J Clin Endocrinol Metab. 2015; 100(6):2291-302. DOI: 10.1210/jc.2014-3868. View

13.

Rudovich N, Rochlitz H, Pfeiffer A . Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes. 2004; 53(9):2359-65. DOI: 10.2337/diabetes.53.9.2359. View

14.

Bennett R, Hamel F, Duckworth W . An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes. 2003; 52(9):2315-20. DOI: 10.2337/diabetes.52.9.2315. View

15.

Blonski W, Kotlyar D, Forde K . Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010; 16(29):3603-15. PMC: 2915420. DOI: 10.3748/wjg.v16.i29.3603. View

16.

Maianti J, McFedries A, Foda Z, Kleiner R, Du X, Leissring M . Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014; 511(7507):94-8. PMC: 4142213. DOI: 10.1038/nature13297. View

17.

Valenti L, Dongiovanni P . CDKN1A: a double-edged sword in fatty liver?. Cell Cycle. 2014; 13(9):1371-2. PMC: 4050133. DOI: 10.4161/cc.28754. View

18.

Matsuda Y, Wakai T, Hirose Y, Osawa M, Fujimaki S, Kubota M . p27 Is a critical prognostic biomarker in non-alcoholic steatohepatitis-related hepatocellular carcinoma. Int J Mol Sci. 2013; 14(12):23499-515. PMC: 3876059. DOI: 10.3390/ijms141223499. View

19.

Michelotti G, Machado M, Diehl A . NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013; 10(11):656-65. DOI: 10.1038/nrgastro.2013.183. View

20.

Pivovarova O, Bernigau W, Bobbert T, Isken F, Mohlig M, Spranger J . Hepatic insulin clearance is closely related to metabolic syndrome components. Diabetes Care. 2013; 36(11):3779-85. PMC: 3816867. DOI: 10.2337/dc12-1203. View